logo
logo
SRZN stock ticker logo

Surrozen, Inc.

NASDAQ•SRZN
CEO: Mr. Craig C. Parker M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-01-11
Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.
Contact Information
171 Oyster Point Boulevard, Suite 400, South San Francisco, CA, 94080, United States
650-489-9000
www.surrozen.com
Market Cap
$234.86M
P/E (TTM)
-2.7
17.8
Dividend Yield
--
52W High
$29.60
52W Low
$5.90
52W Range
91%
Rank43Top 50.7%
3.8
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 3.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q3 2025 Data

Revenue

$983.00K-90.17%
4-Quarter Trend

EPS

-$8.36+1800.00%
4-Quarter Trend

FCF

-$9.06M+34.24%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Significant 2025 PIPE Funding Nine months financing provided 71.3M USD, primarily from the March 2025 PIPE proceeds, bolstering capital resources.
Related Party Revenue Surge Research service revenue reached 2.9M USD for nine months, driven by the TCGFB collaboration agreement executed in 2024.
Strong Cash Position Maintained Cash and equivalents totaled 81.3M USD as of September 30, 2025, supporting operations for at least 12 months.
SZN-8141 IND Filing Expected The company anticipates filing the Investigational New Drug application for SZN-8141 during 2026 to commence clinical studies.

Risk Factors

Net Loss Widened Significantly Nine month net loss increased 66% to 58.9M USD in 2025, driven by higher R&D expenses and non-cash charges.
Operating Expenses Increased Total operating expenses rose 20% to 32.4M USD for nine months, primarily due to 29% growth in R&D spending.
TCGFB Collaboration Terminated Research Collaboration with TCGFB terminated effective November 2025, eliminating future related party revenue streams.
Future Capital Requirements High Expect continued losses and substantial additional capital needed to advance pipeline through clinical development and regulatory submissions.

Outlook

Advance Key Ophthalmology Candidates Strategy focuses on advancing SZN-8141 and SZN-8143 through IND filing and into Phase 1 clinical studies in 2026.
Discontinued SZN-043 Development Development of SZN-043 halted in Q1 2025 due to insufficient early signal of clinical benefit for severe alcohol associated hepatitis.
2025 ATM Program Inactive The 50.0M USD At-the-Market program established in August 2025 has not yet resulted in any common stock sales as of period end.
Maintain Intellectual Property Rights Continued focus on securing and defending patent rights for Wnt platform and product candidates against potential third-party challenges.

Peer Comparison

Revenue (TTM)

AGEN stock ticker logoAGEN
$106.83M
-33.4%
ZNTL stock ticker logoZNTL
$26.87M
-33.8%
MGX stock ticker logoMGX
$25.21M
-51.8%

Gross Margin (Latest Quarter)

SRZN stock ticker logoSRZN
100.0%
+0.0pp
IRD stock ticker logoIRD
99.6%
-0.4pp
TCRX stock ticker logoTCRX
71.8%
-30.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ARMP$422.68M-9.070.3%198.5%
GLSI$356.89M-18.0-1042.8%0.0%
IRD$328.96M-4.9-774.2%3.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
14.5%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Deep Research

Next earnings:Mar 19, 2026
|
EPS:-$1.29
|
Revenue:$661.00K
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data